The objective of the competitive renewal of this joint Ohio State University (OSU)-Nationwide Children's Hospital (NCH) institutional T32 postdoctoral program is to provide interdisciplinary, translational, and state- of-the-art research training in congenital and acquired heart disease. This plan provides a unique opportunity to focus on a continuum of congenital and acquired heart disease from fetal life to senescence and to compare disease mechanisms and outcomes between these diverse populations. The rationale is that advances in heart disease therapy and prevention are most likely to originate from a translational research program that fosters collaboration between physician-scientists and basic scientists. We will expand ongoing efforts to provide an academic environment to cultivate true `bidirectional' research, so that significant clinical problems identified by our physician scientits can be addressed in the laboratory, and key findings at the bench can be rapidly translated to larger animal studies and back to the bedside. This renewal application seeks 6 trainees per year for 5 years with a 2-3 year commitment. Fellows will be selected from MD, DVM, Pharm.D. or PhD trainees who have strong interests in cardiovascular research and are committed to careers in disease-oriented investigations. The Program Directors have a strong-track record in translational cardiovascular research and mentoring and will serve as the primary directors at their respective institutions. The training plan design consists of formal academic courses, seminars and journal clubs to provide trainees with an overview of heart disease and an in-depth cardiac research orientation. Trainees will participate in a tailor-made survival skills course comprised of various modules and workshops related to professional development. Each trainee will perform independent research projects in a mentor's laboratory. The research areas encompassed by the 34 extramurally-funded basic- and clinical- science mentors and 3 participating faculty are represented by their individual affiliations with The Heart Center at NCH and The Davis Heart and Lung Research Institute at Ohio State. A new clinical investigator pathway is added to the training program to enhance clinical research opportunities for MD fellows. The pathway will be directed by J. Phil Saul, MD, an internationally recognized physician-scientist and Chair of Pediatrics. An aggressive underrepresented minority recruitment and retention plan is described to increase trainee diversity. A cross-institutional system will be used to perform trainee and mentor evaluations. Overall metrics to determine success include programatic review by internal and external advisory committees and the successful execution of each trainee's individual development program. Trainee-specific metrics include completion of required coursework, annual evaluation by the mentoring team, and research productivity as assessed by the number of peer-reviewed manuscripts and abstracts, presentations at national meetings and grant submissions (NIH K, R21 and/or foundation grants).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
3T32HL098039-07S1
Application #
9390570
Study Section
Program Officer
Huang, Li-Shin
Project Start
2009-09-01
Project End
2020-08-31
Budget Start
2016-12-01
Budget End
2017-08-31
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Unudurthi, Sathya D; Nassal, Drew; Greer-Short, Amara et al. (2018) ?IV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload. J Clin Invest 128:5561-5572
Best, Cameron; Strouse, Robert; Hor, Kan et al. (2018) Toward a patient-specific tissue engineered vascular graft. J Tissue Eng 9:2041731418764709
El Refaey, Mona; Xu, Li; Gao, Yandi et al. (2017) In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. Circ Res 121:923-929
Koenig, Sara N; Mohler, Peter J (2017) The evolving role of ankyrin-B in cardiovascular disease. Heart Rhythm 14:1884-1889
Best, Cameron; Tara, Shuhei; Wiet, Matthew et al. (2017) Deconstructing the Tissue Engineered Vascular Graft: Evaluating Scaffold Pre-Wetting, Conditioned Media Incubation, and Determining the Optimal Mononuclear Cell Source. ACS Biomater Sci Eng 3:1972-1979
El Refaey, Mona M; Mohler, Peter J (2017) Ankyrins and Spectrins in Cardiovascular Biology and Disease. Front Physiol 8:852
Varghese, Juliet; Potter, Lee C; LaFountain, Richard et al. (2017) CMR-based blood oximetry via multi-parametric estimation using multiple T2 measurements. J Cardiovasc Magn Reson 19:88
Jackson, Jamie L; Gerardo, Gina M; Daniels, Curt J et al. (2017) Perceptions of Disease-Related Stress: A Key to Better Understanding Patient-Reported Outcomes Among Survivors of Congenital Heart Disease. J Cardiovasc Nurs 32:587-593
Jackson, Jamie L; Hassen, Lauren; Gerardo, Gina M et al. (2016) Medical factors that predict quality of life for young adults with congenital heart disease: What matters most? Int J Cardiol 202:804-9
Roof, S R; Boslett, J; Russell, D et al. (2016) Insulin-like growth factor 1 prevents diastolic and systolic dysfunction associated with cardiomyopathy and preserves adrenergic sensitivity. Acta Physiol (Oxf) 216:421-34

Showing the most recent 10 out of 48 publications